PRTN3 and rheumatoid arthritis: reduction (q = 0.009, LDA = 2.1) was associated in RA-advanced patients with ACPA detection at elevated levels (≥3 upper limit of normal [ULN]), which was not the case for the other factors tested, including a moderate/high disease activity and the use of MTX.